Milner Therapeutics Institute Revenue and Competitors

The Milner Therapeutics Institute is a global therapeutic alliance based in Cambridge, dedicated to the conversion of basic science into therapies. Its mission is to foster close collaborative interactions between academia and industry to accelerate medical advancement. The Institute represents a new 'open borders' paradigm, with no physical boundaries and a flexible operational model. Its agenda is to make a different to therapy. The Institute consists of two interrelated components (a) research laboratories at the Cambridge Biomedical Campus and b) an outreach program which involves a Therapeutics Consortium and a set of Affiliated Companies with a therapeutic outlook. The outreach programme is designed to establish a Cambridge ecosystem for therapeutic research and drug discovery. It will enable the development of multiple disease models and the pursuit of drug discovery using diverse modalities, including small molecules and antibodies. This will be accomplished by the active facilitation of academic/industry interactions. Purpose built research laboratories for the Institute have been made possible by a donation from Dr Jonathan Milner and the University of Cambridge. It will be directed by Professor Tony Kouzarides and managed by Dr Kathryn Chapman. Research Laboratories The Institute will have research laboratories within the new Capella Building on the Cambridge Biomedical Campus. The laboratories will be operational in 2018 and will house research groups from the Cambridge research community. A research facility will also be established, accessible to the wider research community as part of the outreach programme. The facility is envisaged to house robotics for customised drug screening and bioinformatics support.